JCI The Journal of Clinical Investigation

Broadly neutralizing antibody-derived CAR-T cells reduce viral reservoir in HIV-1-infected individuals

Bingfeng Liu, … , Linghua Li, Hui Zhang

J Clin Invest. 2021. https://doi.org/10.1172/JCI150211.

Clinical Medicine In-Press Preview AIDS/HIV Clinical trials

BACKGROUND. Chimeric antigen receptor (CAR)-modified T cells have emerged as a novel approach to treat malignant tumors. This strategy has also been proposed for the treatment of HIV-1 infection. We have developed a broadly neutralizing antibody (bNAb)-derived CAR-T cell therapy which can exerted specific cytotoxic activity against HIV-1-infected cells.

METHODS. We conducted an open-label trial of the safety, side-effect profile, pharmacokinetic properties, and antiviral activity of bNAb-derived CAR-T cell therapy in HIV-1-infected individuals who were undergoing analytical interruption of antiretroviral therapy (ART).

RESULTS. A total of 14 participants completed only a single administration of bNAb-derived CAR-T cells. CAR-T administration was safe and well tolerated. Six participants discontinued ART, and viremia rebound occurred in all of them, with a 5.3-week median time. Notably, the cell-associated viral RNA and intact proviruses decreased significantly after CAR-T treatment. Analyses of HIV-1 variants before or after CAR-T administration suggested that CAR-T cells exerted pressure on rebound viruses, resulting in a selection of viruses with less diversity and mutations against CAR-T-mediated cytotoxicity.

CONCLUSIONS. No safety concerns were identified with adoptive transfer of bNAb-derived CAR-T cells. They reduced viral reservoir. All the rebounds were due to preexisting […]

Broadly neutralizing antibody-derived CAR-T cells reduce viral reservoir in HIV-1-infected individuals

Bingfeng Liu[1,2], Wanying Zhang[1], Baijin Xia[1], Shuliang Jing[1], Yingying Du[1], Fan Zou[1,3], Rong Li[1], Lijuan Lu[1], Shaozhen Chen[2], Yonghong Li[2], Qifei Hu[3], Yingtong Lin[1], Yiwen Zhang[1], Zhangping He[1], Xu Zhang[1], Xiejie Chen[2], Tao Peng[4], Xiaoping Tang[2], Weiping Cai[2], Ting Pan[1#], Linghua Li[2#], and Hui Zhang[1#]

[1] Institute of Human Virology,
Key Laboratory of Tropical Disease Control of Ministry of Education,
Guangdong Engineering Research Center for
Antimicrobial Agent and Immunotechnology,
Zhongshan School of Medicine,
Sun Yat-sen University, Guangzhou, Guangdong, China,
[2] Infectious Diseases Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
[3] Qianyang Biomedical Research Institute.
Guangzhou, Guangdong, China
[4] Sino-French Hoffmann Institute
Guangzhou Medical University, Guangzhou, Guangdong, China

Joint corresponding authors

Address correspondence to: Hui Zhang, Institute of Human Virology, Zhongshan School of Medicine, Sun Yat-sen University, No. 74 Zhongshan Road 2, Yuexiu District, Guangzhou, 510080, P.R. China, phone: +86-20-87332588, e-mail: zhangh92@mail.sysu.edu.cn; Linghua Li, Department of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, No.627 Dongfeng East Road, Yuexiu District, Guangzhou, 510060, P.R. China, phone: +86-20-83710816, e-mail: llheliza@126.com; and Ting Pan, School of Medicine, Sun Yat-sen University, No. 74 Zhongshan Road 2, Yuexiu District, Guangzhou, 510080, P.R. China, phone: +86-20-87335703, e-mail: pant8@mail.sysu.edu.cn.

Conflict of interest: The authors have declared that no conflict of interest exists. Aspects of the CAR design are the subject of patent "VC-CAR molecule and use thereof in removing HIV-1 infected cells (US 10,633,432 B2)" which were invented by BF.L, F.Z. and H.Z.

Abstract

BACKGROUND. Chimeric antigen receptor (CAR)-modified T cells have emerged as a novel approach to treat malignant tumors. This strategy has also been proposed for the treatment of HIV-1 infection. We have developed a broadly neutralizing antibody (bNAb)-derived CAR-T cell therapy which can exerted specific cytotoxic activity against HIV-1-infected cells.

METHODS. We conducted an open-label trial of the safety, side-effect profile, pharmacokinetic properties, and antiviral activity of bNAb-derived CAR-T cell therapy in HIV-1-infected individuals who were undergoing analytical interruption of antiretroviral therapy (ART).

RESULTS. A total of 14 participants completed only a single administration of bNAb-derived CAR-T cells. CAR-T administration was safe and well tolerated. Six participants discontinued ART, and viremia rebound occurred in all of them, with a 5.3-week median time. Notably, the cell-associated viral RNA and intact proviruses decreased significantly after CAR-T treatment. Analyses of HIV-1 variants before or after CAR-T administration suggested that CAR-T cells exerted pressure on rebound viruses, resulting in a selection of viruses with less diversity and mutations against CAR-T-mediated cytotoxicity.

CONCLUSIONS. No safety concerns were identified with adoptive transfer of bNAb-derived CAR-T cells. They reduced viral reservoir. All the rebounds were due to preexisting or emergence of viral escape mutations.

TRIAL REGISTRATION. ClinicalTrials.gov number, NCT03240328.

FUNDING. Ministry of Science and Technology of China, National Natural Science Foundation of China, and Department of Science and Technology of Guangdong Province.

Introduction

Antiretroviral therapy (ART) significantly suppresses HIV-1 to an undetectable level in the blood, improves immune function, delays progression of the disease, and decreases mortality in HIV-1-infected patients (1). However, some HIV-1 replication-competent proviruses comprise a latent reservoir, which is quite stable, with a half-life of 44 months, requiring nearly 73.4 years for complete clearance (2, 3). In almost all HIV-1-infected individuals, plasma viral rebound predictably occurs within days after treatment interruption, resulting in the lifelong requirement for ART (4). To achieve durable suppression of viremia without daily therapy, various strategies have been proposed, including long-acting antiretroviral drugs (LA-ARVs), broadly neutralizing antibodies (bNAbs), and chimeric antigen receptor (CAR)-T cells (5). In human clinical trials, viremic individuals who received bNAb therapies showed significant reductions in viremia (6-8). Moreover, HIV-1-infected individuals who received multiple infusions of VRC01 or 3BNC117, two related bNAbs that target the CD4 binding site on the HIV-1 envelope (Env) spike, showed significant viral suppression for 5.6 or 9.9 weeks during analytical treatment interruption (ATI) of ART, respectively (9, 10). Furthermore, a combination therapy of 3BNC117 and 10-1074 maintained the suppression of virus rebound for a median of 21 weeks (11). These findings suggest that immunotherapy with CAR-T cells, if HIV-1-specific bNAb-derived, may also potentially prevent virus rebound in HIV-1-infected individuals after ATI.

The CAR moiety is typically generated by coupling an antibody-derived, single-chain Fv domain to an intracellular T cell-receptor zeta chain and co-stimulatory receptor-signaling domains. The clinical usage of CAR-T cells resulted in complete remission in approximately 83% of lymphocytic leukemia/lymphoma patients (12). Compared to CAR-T cells targeting tumor-associated antigens, such as CD19 and CD20, which are also expressed in normal B-lymphocytes, the HIV-1-specific CAR-T cells target the HIV-1 Env protein, which is only expressed on the surface of virus-producing cells (13-15). Previously, a strategy that fuses the extracellular domain of CD4 with the intracellular domain of the CD3ζ chain (CD4ζ-CAR) was shown to be safe and feasible in HIV-1-infected individuals. However, the antiviral efficacy was modest, and durable control of viral replication in clinical trials was not observed (16-20). In recent years, third and fourth generation intracellular CAR moieties have been developed (12). Moreover, a number of pre-clinical studies on bNAb-derived HIV-1-specific CAR-T cells, *in vitro* and in animal models, have shown the suppression of viral replication or the reduction of virus-producing cells (21-26). In particular, we previously found that the VRC01-derived CAR-T cells effectively reduced the reactivated viral reservoir isolated from HIV-1-infected individuals receiving ART, and the engineered resistance to triple inhibitory receptors, including PD-1, Tim-3, and Lag-3, prevented CAR-T cell exhaustion and improved their efficacy *in vivo* (22, 27).

Here, we report the results of a phase 1 clinical trial to investigate the effect of a single administration of bNAb-derived CAR-T cells, on virus rebound after the

discontinuation of suppressive ART. We have examined whether the adoptive transfer of bNAb-derived CAR-T cells is safe and feasible, leads to long-term immune surveillance, and acts as a potential alternative to antiretroviral drugs to suppress viremia rebound after the discontinuation of ART.

Results

bNAb-derived CAR-T treatment is safe and well tolerated

The clinical trial was divided into four parts: blood drawing and CAR-T cell preparation, CAR-T cell infusion, ATI, and ART re-initiation after viral rebound (Figure 1). The study enrolled 15 participants with chronic HIV-1 infection, all of whom were male, with a median $CD4^+$ T cell count, at enrollment, of 597 cells/μL (range, 380 to 842 cells/μL), and a median duration, from the initiation of ART to study entry, of 4 years (range, 1.8 to 7.5 years) (Table 1, Table 2 and Supplemental Table 1). All participants have not undergone any additional immunotherapeutic intervention besides ART and there were no conditioning regimens before CAR-T cell administrations.

CAR-T cells were successfully generated for 14 of the 15 enrolled patients by infecting the $CD8^+$ T cells with a lentiviral vector expressing the VRC01-28BBz-shPTL CAR moiety (Figure 2A). The transduction efficiency ranged from 34.9% to 77.8%, and the doses of transferred CAR-T cells ranged from 26.2×10^6 to 63.6×10^6 (Supplemental Table 2). Patient 011 was ineligible for receiving an

infusion, because the cells failed to expand adequately (Supplemental Figure 1). Notably, $CD8^+$ Fab^+ CAR-T cells had significantly less PD-1 expression compared to $CD8^+$ Fab^- cells, which suggested that the shRNA cluster can efficiently downregulate the expression of immune checkpoint (Supplemental Figure 2 and 3). The *ex vivo*-expanded CAR-T cells exerted HIV-1 gp160-specific cytotoxicity *in vitro* and some participant CAR-T cells, such as those of Patients 001, 005, 012, and 015, showed more effective lysis of HIV-1_{NL4-3} gp160 expressing cells than others at baseline (Supplemental Figure 4).

The treatment regimen was generally well tolerated in all patients, and no serious adverse events occurred. Complete data on adverse events are provided (Supplemental Table 3). Discontinuation of ART is favorable to evaluate the anti-virus effect of the CAR-T cell therapy. Considering the potential risks for ATI, the ATI was performed when the several criteria are achieved and at least four weeks after CAR-T cell administration (see Methods). Six participants (002, 003, 004, 005, 006, and 015) met the requirements of ATI and consented temporarily suspend the ART. Notably, they showed significant reductions of cell-associated viral RNA and relatively high levels of *in vivo* CAR-T cell persistence (Supplemental Figure 5 and Supplemental Table 4). Participants 001, 007, 010 and 013 also had significant reduction of cell-associated viral RNA and met the other requirements such as CAR-T cell persistence and $CD4^+$ T cell count, however, they dissented to interrupt ART (Supplemental Figure 5 and Supplemental Table 5). The cell-associated viral RNA in Participants 008, 009, 012 and 014 had not shown significant reduction in the

majority of testing points, therefore, the investigators decided not to proceed the ATI for these participants, and they all agreed to maintain ART regimes (Supplemental Figure 5 and Supplemental Table 5). In six participants chosen for ATI, ART was reinitiated on confirmation of viral rebound (the plasma viral load exceeding 200 copies per milliliter), and their plasma viremia was suppressed again. No acute immune response was observed after the infusion of CAR-T cells. The $CD4^+$ T cell counts and the ratio of $CD4^+$ to $CD8^+$ T cells were maintained in the normal range at month-6 after adoptive transfer, while HIV-1 infection was under control with ART (Supplemental Figure 6). During the ATI, the peripheral $CD4^+$ T cell counts decreased in Patients 003 and 004, and the same trend was observed in the ratio of $CD4^+$ cells to $CD8^+$ T cells in Patient 004 (Supplemental Figure 6).

CAR-T treatment delays the viral rebound after ATI

In this clinical trial, six participants met the requirements of ATI and consented temporarily suspend the ART. Notably, they showed significant cell-associated viral RNA reduction and relatively high levels of *in vivo* CAR-T cell persistence (Supplemental Table 4). After ATI, the inhibition of HIV-1 rebound in plasma can sustain as long as 10 weeks (Patient 002). However, the therapy did not lead to long-term suppression of viremia. Viral rebound to more than 200 copies per milliliter occurred after ATI in all six participants, with a median time to rebound of 5.3 weeks (range, 3 to 10 weeks). The longest time of viral suppression was in Patient 002 (10 weeks), while the shortest was in Patient 006 (3 weeks) (Figure 2, B and C). To

179 determine whether the participants who received an infusion of CAR-T cells had a
180 delay in viral rebound after ATI, we introduced a historical control from ATI studies
181 of the AIDS Clinical Trial Group (ACTG) (Supplemental Table 6). This historical
182 control included 155 chronically HIV-1-infected participants whose viral rebound
183 data were captured in four ATI studies without additional immunologic interventions
184 (ACTG 371, A5024, A5068, and A5197) (28-32). The control was selected on the
185 basis of similar inclusion criteria to our study. As compared with 2.3 weeks to plasma
186 viral rebound (HIV RNA level, ≥200 copies per milliliter) in historical controls from
187 the non-interventional ATI studies (28), the CAR-T cell administration led to a longer
188 time to rebound (≥200 copies per milliliter), and 67% of the participants versus 32%
189 of the controls had viral suppression at week 4 (P<0.0001 by a two-sided chi square
190 test), and 17% versus 6%, respectively, had viral suppression at week 8 (P=0.015 by a
191 two-sided chi square test) (28). Meanwhile, as the ART was still used after the CAR-T
192 cell infusions, the plasma HIV-1 levels in the non-ATI group were lower than the
193 detection limit during the observation period.
194 To further analyze other relevant factors impacting viral rebound, we stratified the
195 ART regimens at screening, four of the six ATI participants (002, 004, 005 and 015)
196 received NNRTI-containing regimens (2 NRTI + 1 NNRTI) (Table 1). Their
197 percentages of virologic suppression (plasma viral load <200 copies/mL) after ATI
198 were 100% and 25% at week-4 and week-8, respectively. Correspondingly, the
199 percentages of virologic suppression in historical control (n=99) receiving
200 NNRTI-containing regimens were 44% and 9% at week-4 and week-8 at same viral

load threshold, respectively (28). When we directly compared the proportions of virologic suppression in our study with historical control receiving NNRTI-containing regime by Chi-square test and Fisher's exact test, the results still showed a significantly higher proportion of virologic suppression after CAR-T administrations in NNRTI-receiving group than that in historical control at week-4 ($P<0.0001$) and week-8 ($P<0.0001$) (Supplemental Figure 7). In participants 003 and 006 who receiving non-NNRTI regimens at screening, the plasma viral rebound occurred at week-4 or week-3 respectively. Those receiving CAR-T cell infusions on NNRTI background seem to have a longer timing of virologic suppression. The reason might be associated to the prolonged half-life of NNRTIs. As the ATI cases is limited, we cannot conclude significant differences in durations of viral rebound among different ART regimes. When we compared the proportions of virologic suppression in our study (67% at week-4) to historical control by treatment during acute- (28% at week-4, n=32) or early-infection (29% at week-4, n=48), the results showed a significantly higher proportion of virologic suppression than that in either acute ($P<0.0001$) or early ($P<0.0001$) treatment group (Supplemental Figure 8).

Additionally, protective HLA-I Alleles can be detected in six participants including 001 (B*58:01; B*27), 003 (B*52:01), 005 (B*58:01; B*27), 010 (B*13:02), 013 (B*51) and 014 (B*51) (Supplemental Table 7) (33). The durations of viral suppression in participants 003 and 005 harboring protective HLA-B alleles were 4 and 3 weeks, respectively. They did not show longer durations of viral rebound.

Long-term *in vivo* persistence of CAR-T cell after adoptive transfer

In order to assess the duration of *in vivo* CAR-T cell persistence, quantitative real-time PCR, using primers specific for the VRC01-28BBz-shPTL CAR transgene, was performed on genomic DNA from various time points after CAR-T cell infusions. As described previously, we also detected the *in vivo* persistence of CAR-T cells at an earlier time in some patients (Figure 3A and Supplemental Figure 9) (34, 35). The peak level of modified CAR-T cells detected was 5.7%-0.5% among $CD8^+$ T cells for the 14 patients, immediately after the infusions, and subsequently dropped to less than 0.2% (Figure 3A and Supplemental Figure 9). Nevertheless, the modified CAR-T cells were persistently detectable for more than 44 weeks in all patients (Figure 3A).

To further assess the persistence of HIV-1 Env-specific CAR-T cells after adoptive transfer, Interferon Gamma (IFN-γ) ELISpot assays were performed by incubating the purified $CD8^+$ T cells from HIV-1-infected participants with HIV-1_{NL4-3} Env-expressing cell line at 1: 1 ratio without any additional antigenic peptide addition. As shown in Supplemental Figure 10, the numbers of IFN-γ-secreting T cells from all fourteen participants after CAR-T cell administrations were much higher than those from pre-CAR-T treatment, suggesting that they could develop HIV-1 Env-specific but MHC-I-independent T cell responses after adoptive transfers. With the extension of the observation period to more than 30 weeks after CAR-T cell administrations, although the numbers of IFN-γ-secreting T cells were decreased compared to those at week-3, the HIV-1 Env-specific but MHC-I-independent T-cell responses were still higher than that of pre-CAR-T treatment (Supplemental Figure 10). Considering there

were neither antigen presenting cells (APCs) nor any antigenic peptide in the co-culture system, the MHC-I-independent secretion of IFN-γ was not ascribed to CTL response but the HIV-1 Env-specific CAR-T response. Collectively, the PCR-based CAR assays and function-based analyses both showed that the long-term *in vivo* survival of anti-HIV-1 CAR-T cells.

CAR-T treatment effectively decreases the viral reservoir

It has been shown that HIV-1 unspliced (US) RNA represents intracellular transcripts to estimate the viral reservoir size and is usually much more abundant than the multiply spliced RNA (36-39). Therefore, the cell-associated viral US RNA (CA-RNA) was evaluated, using qRT-PCR, in peripheral $CD4^+$ T cells (Figure 3, A and B, and Supplemental Figure 5). We compared the levels of CA-RNA between fourteen participants prior to the infusions in our study and ART-receiving HIV-infected volunteers. There was no significant difference in CA-RNA between two groups (Supplemental Figure 11A). We found that the levels of CA-RNA in samples from two-week before adoptive transfers were not significantly different with those from week 0, however, they were significantly reduced 3–4 weeks after CAR-T cell administration (Figure 4A). In particular, the CA-RNA was reduced approximately 100-fold after 4 weeks of CAR-T cell administration in Patient 002 (Figure 4A). These results suggested that CAR-T cells effectively reduced these HIV-1 reservoirs. As the CA-RNA increased and the measurable plasma viruses rebounded during the periods of ART discontinuation, the transferred CAR-T cells

expanded accordingly (Figure 3A and B). Unfortunately, CAR-T cells failed to control viral rebound after ATI. As the rebound viruses were suppressed again after ART was reintroduced, the CAR-T cell levels also gradually decreased (Figure 3A). Moreover, the increase in CA-RNA preceded the measurable plasma viral rebound in the periods of ART discontinuation, suggesting that it could serve as a sensitive marker to predict the viremia rebound during HIV-1 treatment interruption (Figure 3B). With the extension of the observation period to more than 30 weeks after CAR-T cell administration, the CA-RNA levels had wide variance among different participants. However, the CA-RNA levels at week 30+ were still significantly lower than those at pre-CAR-T time points ($p=0.0135$) (Figure 4A, left panel). In six participants from ATI group, the CA-RNA levels at week 30+ were higher than those at week 3 or week 4 (Figure 4A, right panel). In contrast, in non-ATI group, except in participant 007, further reductions of CA-RNA at week 30+ were observed in other seven non-ATI participants compared to those at week 3 (Supplemental Figure 12). We have also followed up three ART-receiving patients without any immunologic interventions, their CA-RNA levels remained fluctuating but were not detected significant reduction over observation periods (Supplemental Figure 13). Therefore, the observations of reductions on CA-RNA in our study were most likely ascribed to CAR-T cell infusions.

Through a newly developed intact proviral DNA assay (IPDA) based on droplet digital PCR, we quantitatively analyzed the intact proviruses and defective proviruses in viral reservoirs from the clinical samples before and after CAR-T cell

administration, and found that intact proviruses were also significantly reduced at week-3 after CAR-T cell administration (Figure 4, B and C, Supplemental Figure 14) (40). The same phenomena were also observed in both ATI group or non-ATI group (Figure 4C and Supplemental Figure 15). Interestingly, with the extension of the observation period to more than 30 weeks after CAR-T cell administration, intact proviruses were further decreased compared to those at week-3 in 14 participants (Figure 4C and Supplemental Figure 15). Moreover, there was no difference in the levels of intact proviral DNA between fourteen participants prior to CAR-T infusions in our study and ART-receiving HIV-infected volunteers (Supplemental Figure 11B). Given that CAR-T cells can be persistently detectable in peripheral blood for as long as 44 weeks, both CA-RNA and intact proviral DNA levels can be observed decreased even 6 months after CAR-T infusions, these results further suggested that the long-term persistence of CAR-T cell have the potential to undermine the viral reservoir.

CAR-T treatment restricts the rebound viruses genetically

To characterize the rebounding viral populations, single-genome sequencing of HIV-1 *env* genes from $CD4^+$ T cell samples was performed before CAR-T cell administration and the first and second weeks after detectable viremia (available in six participants). Previous studies have suggested that, without any additional intervention besides ART, viral rebound after ATI is consistently polyclonal because of the reactivation of multiple latent viruses (41-43). In contrast, the CD4 binding site-directed neutralizing

311 antibodies exert ongoing selection pressure on the conserved epitope of HIV-1 Env
312 and rebound viruses clustered into relatively low-diversity lineages (44-46). Genetic
313 evidence of CAR-T-mediated restriction of viral rebound was assessed by analyzing
314 the clonality of rebound virus or by enumerating genetically distinct virus populations
315 composed of rebound viruses. In Patients 002, 004, 006, and 015, the cell-associated
316 viruses from pre-CAR-T treatment with chronic infection, formed characteristic
317 diverse phylogenetic trees; in contrast, rebound viruses in cells were significantly
318 distinct from those of pre-CAR-T treatment, and clustered into relatively
319 low-diversity lineages (Figure 5 and Supplemental Figure 16). Additionally, the
320 genetic diversities of full-length Env sequences from the post-CAR-T cell sample
321 were also significantly lower than those from the pre-CAR-T sample in a non-ATI
322 participant (Patient 007) (Supplemental Figure 17). These findings suggested that
323 HIV-1-specific CAR-T cells were able to exert pressure on rebound viruses and
324 reduced the number of HIV-1 intact proviruses at different locations, resulting in the
325 emergence of genome-distinct viral mutations. In contrast, the rebound viruses in
326 Patient 003 clustered into multiple genetically distinct lineages that aligned
327 throughout the pre-CAR-T treatment virus phylogeny, indicating possible pre-existing
328 resistance (Figure 5) (41, 42).
329
330 **CAR-T treatment leads to the generation of resistant viruses**
331 According to previous reports, the VRC01-antibody binding footprint was represented
332 by Env residues in loop D, CD4 binding sites, β20/β21 regions, and the base of the V5

loop, which are known as VRC01 contact residues, and many VRC01-antibody-resistant strains were identified in chronically infected patients (46-53). We generated sequence alignment and modified longitudinal logo plots to reveal mutations in the predicted VRC01-antibody-binding regions between pre-CAR-T treatment and rebound virus populations (54). We also found a number of mutations in the rebound viruses in or near the VRC01-antibody-binding epitopes, mainly in the inner domain, V2 loop, loop D, CD4-binding site, and the V5 loop, from five of the six participants (Figure 6A). In Patient 002, a change was found at position 197, a potential *N*-linked glycosylation (PNLG) site in the V2 region, where serine (S) was replaced by asparagine (N) (47). In Patient 004, mutations were found at position 186 on the V2 loop and positions 279 and 280 on Loop D (46, 47, 53). In Patient 006, glycine (G) was replaced by alanine (A) at position 281 on Loop D, isoleucine (I) was replaced by asparagine (N) at the PNLG site at position 461, and the residues 463–466 were also changed in the V5 loop (50, 53). These outcomes suggested bNAb-derived CAR-T-mediated selective pressure on rebound viruses (Figure 6A and Supplemental Figure 18). However, in Patient 003, some signature substitutions, such as threonine 278, of resistant strains were found in the viruses from pre-CAR-T treatment, also suggesting a possible pre-existing resistance (46).

To further validate the HIV-1-specific CAR-T-mediated selective pressure on rebounding viruses, we examined the outgrowth of replication-competent viruses from pre-CAR-T latent reservoir and rebound reservoir. PBMCs were isolated from healthy donors and divided into two populations, the $CD8^+$ T lymphocytes were used

355 to generate bNAb-derived CAR-T cells, while the $CD4^+$ T lymphocytes were used as
356 target cells for outgrown HIV-1 infection. Six days after HIV-1 infection, the
357 antiretroviral compounds were added to the $CD4^+$ T cell culture to inhibit virus
358 production and prevent further infection events. After approximately 8 days, the virus
359 production significantly decreased to the lower limit for p24 detection, and infected
360 $CD4^+$ T cells were close to quiescence (22). We then withdrew anti-HIV-1 drugs to
361 mimic the *in vivo* viral rebound process, and added autologous bNAb-derived CAR-T
362 cells. As shown in the groups infected by viruses from pre-CAR-T latent reservoirs of
363 Patients 002, 004, and 015, viral production was significantly suppressed following
364 co-culture with CAR-T cells (Figure 6B, left panel). However, in the groups infected
365 by viruses from rebound reservoirs of the same patients, the CAR-T cells exhibited
366 only limited inhibitory effect on viral propagation (Figure 6B, right panel). This
367 experiment further validated the capacity of bNAb-derived CAR-T therapy to drive
368 resistant viruses during ATI. Moreover, the CAR-T cells failed to inhibit viral
369 propagation even in the $CD4^+$ T cells infected by viruses from the pre-CAR-T latent
370 reservoir of Patient 003, suggesting a possible pre-existing resistance (Figure 6B, left
371 panel). Notably, regardless of the time to rebound, resistance to HIV-1-specific
372 CAR-T cells occurred in 2/3 of the participants, as determined with a specific
373 cytotoxicity assay (Figure 6C). Collectively, the sequence- and function-based
374 analyses showed that the CAR-T-resistant viruses could be pre-existing or CAR-T
375 treatment-driven during ATI.
376

Discussion

CAR-T cell therapy was introduced to HIV-1 clinical care in 1994, but little, if any, antiviral efficacy and durable control of viral replication were observed (16-20). However, these earlier studies were performed using CD4 or less potent antibody-derived Fv as the extracellular domain. Additionally, CARs from the first generation had no co-stimulatory domains. Here, we investigated whether the bNAb-based third generation CAR-T cell therapy can reduce HIV-1 reservoir and maintain viral suppression during ATI in HIV-1-infected individuals. We found that a single adoptive transfer of bNAb-derived CAR-T cells generated long-term *in vivo* persistence for more than 44 weeks in all 14 patients, and no safety concerns were identified. In chronically HIV-1-infected individuals who were undergoing ATI, CAR-T cell therapy delayed plasma viral rebound as compared with historical controls.

The viral reservoir is dynamically changed under the pressure of antiretroviral drugs or immune systems. At the early time, the CAR-T cells expand *in vivo* and could efficiently reduce viral reservoir, consequently leading to a significant decrease of CA-RNA. In ATI group, as the replication-competent provirus could complete life cycle after ART discontinuation, the viral escape mutations have opportunity to quickly develop. When the plasma viraemia rebounded due to the emergence of CAR-T-resistant variants during the periods of ATI, the CA-RNA also significantly increased accordingly. Even several months after the plasma viral load was lower than

399 the detection limit again after ART re-initiation, the levels of CA-RNA was still
400 higher than the pre-ATI time-points. However, within the non-ATI group, the
401 development of resistant variants is quite difficult because the replication-competent
402 provirus is unable to complete its replication. The surviving CAR-T cells could keep
403 cleaning the target cells which occasionally express gp120 on the surface of latently
404 infected cells, which could lead to the eventual decrease of CA-RNA and intact
405 proviruses.
406
407 Although quantitative and qualitative viral outgrowth assays (Q^2VOA) have been
408 frequently used to analyze the replication-competent latent viral reservoir in HIV-1
409 infected individuals (55), these quantitative Q^2VOA underestimate the reservoir size,
410 because one round of activation does not induce all proviruses (56). Additionally, it is
411 inadequate for long-term follow-up by performing the Q^2VOA requiring a large
412 number of $CD4^+$ T cells from patients. In order to measure the effect of CAR-T
413 therapy on the viral reservoir, we chose CA-RNA and intact provirus detection assay
414 (IPDA) as the biomarkers to measure HIV-1 reservoir size (39, 40). The CA-RNA has
415 received much attention in recent years as a surrogate measure of the efficiency of
416 HIV-cure-related clinical trials and HIV-1 latency reversion (39). We notice that the
417 levels of CA-RNA were relatively high and fluctuating in some of the participants, the
418 wide variance of CA-RNA may be related to several aspects, such as infection time
419 before diagnosis, treatment time, immunologic characteristics, and different ART
420 regimes. The intermittent fluctuation and slight increasement of viral RNA level may

not lead plasma viral rebound in participants without ATI, because a part of the transcripts is defective, and production of infectious virions is regulated by multiple post-transcriptional levels (57). IPDA has recently been described as a more accurate method of measuring the HIV-1 reservoir that separately quantifies intact and defective proviruses, and there are strong correlations between IPDA and Q^2VOA measurements in the same infected individuals (40). According to previous study, the half-life of the intact provirus is 7.1 years under ART (58). In our clinical study, intact proviruses were significantly reduced at week-3 and further decreased at week 30+ after CAR-T cell administration. These findings suggested that CAR-T cell therapies could accelerate HIV-1 reservoir depletion based on ART regimes. Since the DNA samples of the ART-receiving HIV-infected volunteers form long-term follow-up visits were not available, we cannot perform parallel comparison between CAR-T receiving participants and control cohort at multiple time points, which is a limitation of our current study. More quantitative IPDA analysis at multiple time points regarding the decay of viral reservoir under the pressure of cellular therapies merits being further investigated.

Although we did not check the binding-affinity of every single envelope protein from rebound viruses to VRC01-scFv, we found that, as shown in Figure 6 B and C, at least several strains among the rebound viruses turned to resistance against the $CD8^+$ CAR-T cell-mediated cytotoxicity. As for whether the binding to escaped envelope may still occur or what level of binding-affinity will be sufficient to trigger killing by

the CAR-T cells, further investigations and related researches are required and will contribute to novel CAR design and cure-directed therapeutic strategies.

In our clinical study, participant 002 with highest $CD4^+$ T cell count had the longest time to viral rebound and participant 006 with minimal nadir $CD4^+$ T cell count had the earliest viral rebound. The results suggest that the higher $CD4^+$ T cell counts might lead to a longer time to viral rebound due to a kind of collaboration between $CD4^+$ T-cells and $CD8^+$ CAR-T cells (59-61). However, as the ATI cases is limited, we cannot conclude significant correlations in the study. A previous ATI study showed that viral rebound generally occurs quickly after treatment interruption and confirm the rarity of post-treatment controllers, and there were no significant differences in screening $CD4^+$ T cell count by timing of viral rebound (28). Nevertheless, the $CD4^+$ T cell counts and the ratio of $CD4^+$ to $CD8^+$ T cells represent important indicators of the immune reconstitution. Increased $CD4^+$ T cell counts during ART treatment were positively correlated with $CD8^+$ T cell counts/function and HIV-1 DNA reduction (59). Thus, the correlations between the $CD4^+$ T cell counts and the time of viral rebound during CAR-T cell therapy need further explore.

Both sequence-based and specific cytotoxicity analyses suggest that the rebound viruses after adoptive transfer are CAR-T cell-resistant, suggesting that CAR-T cells could effectively function by restricting viral replication, and force them to generate escape mutations. Alternatively, as mutations create HIV-1 resistance to CAR-T cell

therapy, future clinical trials may consider the administration of a combination of CAR-T cells recognizing multiple distinct regions on the HIV-1 Env to potentiate their long-term surveillance on the viral reservoir. Additionally, the efficacy of CAR-T cell therapy in chronically HIV-1 infected patients will be dependent in part on whether these persons have resistant strains to that extracellular scFv of CAR moiety in persistent viral reservoirs. A pre-clinical screening to select proper patients could be necessary. Moreover, a combination with other testing methods is needed for more accurate measurement of viral reservoir size during HIV-cure-related clinical trials, such as Q^2VOA, HIV total and integrated DNA and induced p24 SIMOA, etc.(62).

Several clinical studies reported that infusion of CCR5 gene-edited hematopoietic stem and progenitor cells (HSPCs) or $CD4^+$ T cell to HIV-1-infected individuals (63-65). These studies showed that the replacement of part of the immune system through genetic engineering to produce $CD4^+$ T cells resistant to HIV-1 infection was a feasible strategy. In contrast to replacement of the immune system, we utilized a different strategy to rebuild immune surveillance in HIV-1-infected-patients through adoptive transfer of *ex vivo* expanded HIV-1-specific $CD8^+$ CAR-T cells, which can directly target virus-producing cells. Of note, in nonhuman primate model of ART-suppressed HIV-1 infection, the investigators optimized CAR-T cell production to maintain central memory subsets, and further boosted robust *in vivo* expansion through supplemental infusion of HIV-1 Env or immune checkpoint blockade (66). The modifications significantly delayed viral rebound compared with controls and

would provide guidance on future CAR-T clinical studies aiming HIV functional cure. Although so far only a modest delay in the time to viral rebound relative to historical controls was achieved by either therapy, the results still provided certain directions for further investigation of therapeutic interventions. Given that the CCR5 gene-edited $CD4^+$ T cell infusion could augment preexisting HIV-specific immune responses, the collaboration of CCR5 gene-edited $CD4^+$ T and HIV-1-specific $CD8^+$ CAR-T cells might be developed as a therapeutic modality for eradicating viral reservoir in clinic (65, 67).

The establishment of potent HIV-1-specific immune surveillance is a feasible approach for long-term suppression of the reactivated latent viral reservoir without continuation of ART. Although bNAb treatment, especially the combination of two bNAbs targeting different sites on gp120, has achieved durable control over the viral reservoir, they cannot persistently remain *in vivo*. In contrast, single administration of CAR-T cells can potentially maintain long-term survival *in vivo* (68, 69). It has been reported that the half-life of CD4ζ CAR-T cells *in vivo* could be as long as 10 years (19). Although we have no direct evidence yet for the role played by triple knock-down of PD-1, Tim-3, and Lag-3 with shRNA in CAR-T cells, our data also suggested a long-term *in vivo* survival of anti-HIV-1 CAR-T cells. In such situations, CAR-T cells could function as a “living drug”. Furthermore, it is anticipated that more potent scFv-based CAR-T cells will be generated by improving the CAR moiety design, either by selecting more specific scFvs targeting various sites of viral Env, or

enhancing their capability of self-renewal, exhaustion prevention, tissue distribution, etc. Moreover, the good manufacturing practice compliant manufacturing protocols, clinical safety, and efficacy require further optimization (70). We expect that the cellular therapies, in combination with application of bNAbs or LA-ARVs, would eradicate the persistent HIV-1-producing cells, by enhancing immune surveillance and maintaining a long-term viral suppression without the continuation of ART.

Methods

Study Oversight

The study was designed to mainly assess the safety and feasibility of the adoptive transfer of gp120-specific bNAb-derived CAR-T cells into HIV-1 positive patients. This clinical trial recruited participants who had chronic HIV-1 infection with fully suppressed plasma viremia while receiving ART (clinically stable on ART regimen for at least 12 months with undetectable HIV-1 RNA level; the screening $CD4^+$ T cell count $\geq$ 350 cells/μL within 14 days prior to study entry). Detailed inclusion and exclusion criteria are listed in clinical protocol in the supplementary materials. Study participants were not prescreened for sensitivity of the infected-cells to CAR-T cell cytotoxicity and have not undergone any additional immunotherapeutic intervention besides ART.

Genetic Modification and CAR-T Cell Preparation

Autologous peripheral blood mononuclear cells (PBMCs) were collected from

50-60ml peripheral blood of HIV-1 infected patients and separated on the basis of CD8 expression using the CliniMACS system by following the manufacturer's instructions. The sorted population was more than 95% $CD8^+$ T cells. $CD8^+$ T cell products were stimulated with paramagnetic antibodies (anti-CD3 and anti-CD28) and 130 IU IL-2 (SL Pharm), then the cells were transduced with the VRC01-28BBz-shPTL transgene to express a gp120-specific bNAb-derived CAR containing CD28 and 4-1BB (CD137) costimulatory domains (22), followed by a herpes simplex virus-1 thymidine kinase (TK) and a truncated CD19 gene as the suicide genes (71). A combination of sh-PD-1, sh-Lag-3, and sh-Tim-3 was also inserted into the vector (27). Twelve hours after infection, the CAR-transduced $CD8^+$ T cells were washed by saline and resuspend Immuno-Cult-XF T cell Expansion medium (STEMCELL Technologies) with 130 IU IL-2 (SL Pharm), the concentration of cells was maintained at 10^6 cells/ml. Every two days, the volume of the culture was adjusted according to the cell concentration (10^6 cells/ml) and supplemented IL-2. The CAR-modified autologous T cells were then expanded in flasks until the targeted cell dose was reached. The CAR-T cells were infused after 2 to 3 weeks expansion *ex vivo*, and the target cell dose range is at least 5×10^7 $CD3^+$ $CD8^+$ cells. Release criteria for the expanded $CD8^+$ T cells were as follows: sterility by Chinese Pharmacopeia (2015), negative fungal, and mycoplasma testing, negative Gram stain, endotoxin less than 5 EU/mL, more than 90% viability by Trypan Blue exclusion, $CD3^+$ $CD8^+$ T cells $\geq$ 95%, transduction efficiency (CAR^+ $CD8^+$) $\geq$ 30%, and gp120-specific cytotoxicity of more than 40% lysis at 100:1 E:T ratio. The doses of total transferred

cells were between 5.00×10^7 to 1.00×10^8.

Treatment Procedures, Study Objectives, and Study Outcomes

In the study, 15 participants were enrolled in this study and 14 participants received single administration of bNAb-derived CAR-T cells (5.00×10^7 to 1.00×10^8). There were no conditioning regimens before CAR-T cell administrations. After the CAR-T cells transfer, 6 participants discontinued ART and were followed at weekly intervals until they had a confirmed $CD4^+$ T cell count of less than 350 cells/μl or viral rebound, which was defined as an HIV-1 RNA level of 200 copies or more per milliliter. On confirmation of viral rebound or a decrease in $CD4^+$ T cells, participants reinitiated ART and were followed at weekly intervals until the HIV-1 viral load was less than 20 copies/μl.

The primary objective of the study was to assess the safety and side-effect profile of single dose of bNAb-derived CAR-T cells administered to persons with viremia suppressed to below detectable levels. Secondary objective was to evaluate the pharmacokinetic characteristics of CAR-T products. Key exploratory objectives were the size of HIV-1 reservoir after CAR-T cells administration and the genetic and phenotypic characterization of the rebound viruses. Post hoc analyses of the sequence diversity at the time of viremia rebound and the cytotoxic capacity of CAR-T cells against autologous HIV-1 before and after adoptive transfer were performed.

Anti-retroviral Therapy Interruption

With informed consents again from the patients, analytical interruptions of ART were performed to investigate the anti-virus effect of bNAb-derived CAR-T cell therapy. The ART interruption was performed when the following criteria were achieved. 1. A written informed consent is provided by the patient; 2. No adverse events at the time of interruption; 3.The $CD4^+$ T cell counts maintain in a normal range (> 400 cells/μl peripheral blood); 4. The plasma viral load is under the detectable level (< 20 copies per milliliter); 5. The CA-RNA is reduced at least 50%; 6. *In vivo* CAR-T cells can be persistently detectable (> 100 copies per million $CD8^+$ T cells). To prevent the risk of efavirenz monotherapy and the emergence of resistant strains after stopping ART, the individuals whose regimens contained efavirenz stop taking it one week before discontinuing the other agents. The individuals with integrase inhibitor-based or protease inhibitor-based regimes discontinue three ART agents simultaneously. When all the ART agents are discontinued, the time of plasma viral suppression begins to measure.

To protect the patient from adverse events induced by virus rebound, anti-virus treatment will be reinitiated when any of the following items was fulfilled. 1. The plasma viral load exceeding 200 copies per milliliter; 2. The $CD4^+$ T cells decrease under 350 cells/μl; 3. Any AIDS-related opportunistic infections are observed; 4. Occurrence of severe CAR-T–related adverse events; 5. Request for reinitiating anti-retroviral therapy by the patient.

Quantitative PCR to detect CAR-modified T cells

Patient PBMCs collected at baseline and at serial time points after CAR-T-cell infusions were collected and separated by Ficoll centrifugation and then cryopreserved. Batched cells were thawed and primary human $CD8^+$ T cells were obtained from PBMCs by positive magnetic selection through Anti-Human CD8 Magnetic Particles - DM, BD-IMag^{TM}. The genomic DNA was harvested using an AllPure Total DNA/RNA Micro Kit (Magen). The CAR transgene was detected by performing quantitative PCR as previously described, using either a primer amplifying the fragment spanning the junction of the CD3ζ domian and adjacent Flag domain (forward primer: 5'-GCCTTTACCAGGGTCTCA-3', reverse primer: 5'-ACTTATCGTCGTCATCCTTG-3'), or a primer amplifying the fragment of VRC01 scFv (forward primer: 5'-ATTTTTTGGCCAGGGGACC-3', reverse primer: 5'-AGGATTCTCCTCGACGTCACC-3') (22). Quantitative real-time PCR was performed in triplicate using SYBR Premix ExTaq II Kit (Takara), in a C1000 Touch Thermal Cycler (BIO-RAD CFX96^{TM} Real-Time System) (22). Copy numbers per microgram of genomic DNA, generated from a standard curve of 10-fold serial dilutions of purified plasmid, were used to calculate the percentage of CAR^+ cells among $CD8^+$ T cells, assuming 1 copy/cell.

Quantitative real-time RT–PCR analysis.

Primary human $CD4^+$ T cells were obtained from PBMCs by negative magnetic selection through Human $CD4^+$ T Lymphocyte Enrichment Set-DM, BD-IMag^{TM}. Total RNA was isolated with Trizol reagent (Life Technologies) and then subjected to

cDNA synthesis using PrimeScript RT reagent Kit (Takara). All primers were annealed at 37°C and RT was processed at 42°C. Quantitative PCR was performed with SYBR Premix ExTaq II Kit (Takara) by following the manufacturer's instructions. The expressions of HIV-1 unspliced RNAs were determined by real-time qRT-PCR with the primer pair SK38 (5'-ATAATCCACCTATCCCAGTAGGAGAAA-3') and SK39 (5'-TTTGGTCCTTGTCTTATGTCCAGAATGC-3'). An *in vitro*-synthesized HIV-1 RNA, after quantification, was used as the external control for measuring CA-RNA (72). Quantification was normalized to the housekeeping gene GAPDH or β-actin.

Intact proviral DNA assay (IPDA)

The procedures for IPDA described previously were followed with minor modifications (40, 73). In general, the IPDA is performed on DNA from 2×10^6 $CD4^+$ T cells. Genomic DNA is extracted using the AllPure Total DNA/RNA Micro Kit (Magen) with precautions to avoid excess DNA fragmentation. Quantification of intact, 5'deleted, and 3'deleted and/or hypermutated proviruses was carried out using primer/probe combinations optimized for subtype B HIV-1. The primer/ probe mix consists of oligonucleotides for two independent hydrolysis probe reactions that interrogate conserved regions of the HIV-1 genome to discriminate intact from defective proviruses (Supplemental Table 8). HIV-1 reaction A targets the packaging signal (ψ) that is a frequent site of small deletions and is included in many large deletions in the proviral genome. The ψ amplicon is positioned at HXB2 coordinates

692–797. This reaction uses forward and reverse primers, as well as a 5'6-FAM-labeled hydrolysis probe. Successful amplification of HIV-1 reaction A produced FAM fluorescence in droplets containing ψ, detectable in channel 1 of the droplet reader. HIV-1 reaction B targets the RRE of the proviral genome, with the amplicon positioned at HXB2 coordinates 7736–7851. This reaction used forward and reverse primers, as well as two hydrolysis probes: a 5'VIC labeled probe specific for wild-type proviral sequences, and a 5'unlabelled probe specific for APOBEC3G/H hypermutated proviral sequences (Supplementary file 2). Successful amplification of HIV-1 reaction B produced a VIC fluorescence in droplets containing a wild-type form of RRE, detectable in channel 2 of the droplet reader, whereas droplets containing a hypermutated form of RRE were not fluorescent.

Droplets containing HIV-1 proviruses were scored as follows. Droplets positive for FAM fluorescence only, which arises from amplification, was scored as containing 30 defective proviruses, with the defect attributable to either APOBEC3G mediated hypermutation or 3' deletion. Droplets positive for VIC fluorescence only, which arises from wild-type RRE amplification, was scored as containing 5' defective proviruses, with the defect attributable to 5' deletion. Droplets positive for both FAM and VIC fluorescence was scored as containing intact proviruses. Double-negative droplets contained no proviruses or rare proviruses with defects affecting both amplicons.

Viral outgrowth.

Recovery and amplification of replication-competent viruses were described previously (55, 74). Briefly, 1 × 10^6 $CD4^+$ T cells from HIV-1-infected individuals were stimulated by 1×10^7 irradiated allogeneic PBMC from uninfected donors and the 1 μg/ml PHA-M at day 1, and typically, three additions of 5×10^6 activated $CD4^+$ lymphoblasts from uninfected donors as target cells were added for HIV-1 outgrowth at day 2, day 7 and day 14, respectively. The cells were cultured in RPMI-1640 media + IL-2 (10 ng/ml, recombinant human, R&D Systems) all the time. After 14 days co-culture, the recovered viruses were harvested and tested for HIV-1 p24 protein.

***In vitro* HIV-1 infection and drug withdrawal model**.

In vitro HIV-1 infection model was previously described with minor modifications (22). Briefly, the PBMCs from healthy donors were stimulated by adding 1 mg/ml PHA and 10 ng/ml IL-2 to the conditioned RPMI1640 media with 10% heat-inactivated fetal bovine serum and antibiotics for two days before isolation of $CD4^+$ T cells. $CD4^+$ T cells were infected with an outgrown HIV-1 from patients (p24 titer of 1 ng/ml). Three hours after infection, the culture media was changed by centrifugation. The infected $CD4^+$ T cells were cultured in basal media + IL-2 (10 ng/ml, recombinant human, R&D Systems) and further incubated at 37°C in a humidified incubator with 5% CO_2. Six days after HIV-1 infection, azidothymidine (Zidovudine, Sigma-Aldrich) and lopinavir (Sigma-Aldrich) were added into the $CD4^+$ T cell culture both at 50 μM to inhibit virus production and prevent further infection events. The cells were then cultured in the presence of low-concentration of

IL-2 (1 ng/ml). Anti-HIV-1 drugs were withdrawn when the viral production was significantly decreased to the marginal level for p24 detection (about 6-8 day after drugs adding). Then, 0.5 $\times 10^6$ $CD4^+$ T cells were mixed with autologous CAR-T cells or control $CD8^+$ T cells at 1: 1 ratio in the conditioned media plus IL-2 (10 ng/ml) at 1 ml in 24-well plate. Every two days the cultures were tested for HIV-1 p24 antigen with the HIV-1 p24 Antigen Assay kit by following the manufacturer's instructions.

Genetic diversity analysis of activated HIV-1 viruses.

HIV-1 RNA extraction and single-genome amplification was performed as previously described (11, 75, 76). In brief, HIV-1 RNA was extracted from cell and plasma samples followed by first-strand cDNA synthesis using HiScript II 1st Strand cDNA Synthesis KIT (Vazyme). cDNA synthesis for cell/plasma-derived HIV-1 RNA was performed using the antisense primer envB3out 5′-TTGCTACTTGTGATTGCTCCATGT-3′. The gp160 was amplified using envB5out 5′-TAGAGCCCTGGAAGCATCCAGGAAG-3′ and envB3out 5′-TTGCTACTTGTGATTGCTCCATGT-3′ in the first round and in the second round with nested primers envB5in 5′-CACCTTAGGCATCTCCTAT GGCAGGAAGAAG-3′ and envB3in 5′-GTCTCGAGATACTGCTCCCACCC-3′. PCRs were performed using Phanta Max Super-Fidelity DNA Polymerase (Vazyme) and run at 94 °C for 2 min; 35 cycles of 94 °C for 15 s, 55 °C for 30 s and 68 °C for 4 min; and 68 °C for 15 min. Second-round PCR was performed with 1 μl of the PCR product from the first round as template and Phanta Max Super-Fidelity DNA

Polymerase (Vazyme) at 94 °C for 2 min; 45 cycles of 94 °C for 15 s, 55 °C for 30 s and 68 °C for 4 min; and 68 °C for 15 min. Amplicons were run on precast 1% agarose gels (BIOWESTE) and the PCR products were proceeded to deoxyadenosine (A)-tailing at the 3'-end of the PCR products utilizing Ex Taq DNA polymerase (Takara) without thermal cycling as follows: 95°C, 5 min; 72°C, 30 min. The A-tailed PCR products were TA-ligated into pMD-18 T vector (Takara).

Sequence and phylogenetic analysis.

Nucleotide alignments of intact *env* sequences were translation-aligned using MEGA 7. Sequences with premature stop codons and frameshift mutations that fell in the gp120 surface glycoprotein region were excluded from all analyses. The sequences from each group were aligned using MUSCLE. The average genetic distance between one give clone and the relevant entire population were calculated by MEGA 7 and represented as genetic diversity index. The phylogenetic bootstrap trees were generated for each sample using maximum likelihood method with 1000 bootstrap replications implemented in MEGA 7 to depict the global landscape of HIV-1 diversity. Logograms were generated using the Weblogo 3.0 tool. To analyze changes between latent reservoir and rebound viruses, Env sequences were aligned at the amino acid level to a HXB2 reference using BioEdit. Nucleotide sequences have been submitted to GenBank.

Cytotoxicity determination.

729 The specific killing activity of pre-stimulated $CD8^+$ T cells towards Jurkat or
730 HEK293T cells expressing HIV-1 Env glycoprotein at indicated ratios was measured
731 after co-culture for 8 hours by lactate dehydrogenase assay using the CytoTox 96
732 nonradioactive cytotoxicity kit (G1781, Promega, as described previously (22, 27).
733 The manufacturer's instructions were followed. Absorbance values of wells
734 containing effector cells alone and target cells alone were combined and subtracted as
735 background from the values of the co-cultures. Wells containing target cells alone
736 were mixed with a lysis reagent for 30 min at 37˚C and the resulting luminescence
737 was set as 100% lysis. Cytotoxicity was calculated by using the following
738 formula: %Cytotoxicity = (Experimental – Effector spontaneous – Target spontaneous)
739 / (Target maximum – Target spontaneous) × 100%.
740
741 **Cell lines.**
742 HEK293T and Jurkat cell lines were obtained from ATCC. Jurkat-$gp160_{NL4-3}$ cells
743 were established by the infection of Jurkat cells with recombinant lentiviruses
744 carrying $HIV\text{-}1_{NL4-3}$ Env-IRES-GFP moiety, followed by sorting GFP^{high} cells.
745
746 **Statistics.**
747 We used the Pearson's Chi Square test or the Fisher's exact test (two-sided) as
748 appropriate to analyze differences in proportions of virologic suppression between
749 CAR-T cell infusion group and historical controls. $P<0.05$ was considered
750 significant. The CA-RNA or IPDA values were firstly assessed whether they

conformed to normal distribution by Shapiro-Wilk test. Since not all of the variables conformed to normal distribution, we used multiple Wilcoxon matched pairs signed rank test to compare the data. Two-way ANOVAs were performed with Bonferroni correction for multiple comparisons. We have adjusted P values for multiple comparisons using Bonferroni corrections. Other P-values of statistical analyses such as CAR-T cell-mediated cytotoxicity were calculated using the two-tailed unpaired Student's t-test with equal variances. We generated graphics with GraphPad Prism 5.0 software.

Study approval.

This clinical trial was approved by the Institutional Review Board (IRB) of Guangzhou Eighth People's Hospital and Sun Yat-sen University (protocol 201803040002). The written informed consents were provided from all patients prior to their enrollment on the clinical trial. This clinical trial is registered at ClinicalTrials.gov (NCT03240328). The study was conducted in accordance with legal and regulatory requirements, as well as the general principles set forth in the International Ethical Guidelines for Biomedical Research Involving Human Patients (Council for International Organizations of Medical Sciences 2002), Guidelines for GCP (International Conference on Harmonization, 1996), and the Declaration of Helsinki (World Medical Association 1996 & 2008). In addition, the study was conducted in accordance with the protocol and applicable local regulatory requirements and laws.

References

1. Sengupta S, and Siliciano RF. Targeting the Latent Reservoir for HIV-1. *Immunity.* 2018;48(5):872-95.
2. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. *Nature medicine.* 2003;9(6):727-8.
3. Buzon MJ, Sun H, Li C, Shaw A, Seiss K, Ouyang Z, et al. HIV-1 persistence in CD4+ T cells with stem cell-like properties. *Nature medicine.* 2014;20(2):139-42.
4. Chun TW, Davey RT, Jr., Engel D, Lane HC, and Fauci AS. Re-emergence of HIV after stopping therapy. *Nature.* 1999;401(6756):874-5.
5. Liu B, Zhang W, and Zhang H. Development of CAR-T cells for long-term eradication and surveillance of HIV-1 reservoir. *Current opinion in virology.* 2019;38:21-30.
6. Lynch RM, Boritz E, Coates EE, DeZure A, Madden P, Costner P, et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. *Science translational medicine.* 2015;7(319):319ra206.
7. Caskey M, Schoofs T, Gruell H, Settler A, Karagounis T, Kreider EF, et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. *Nature medicine.* 2017;23(2):185-91.
8. Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP, Jr., Buckley N, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. *Nature.* 2015;522(7557):487-91.
9. Bar KJ, Sneller MC, Harrison LJ, Justement JS, Overton ET, Petrone ME, et al. Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. *The New England journal of medicine.* 2016;375(21):2037-50.
10. Scheid JF, Horwitz JA, Bar-On Y, Kreider EF, Lu CL, Lorenzi JC, et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. *Nature.* 2016;535(7613):556-60.
11. Mendoza P, Gruell H, Nogueira L, Pai JA, Butler AL, Millard K, et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. *Nature.* 2018;561(7724):479-84.
12. June CH, O'Connor RS, Kawalekar OU, and Ghassemi S. CAR T cell immunotherapy for human cancer. 2018;359(6382):1361-5.
13. Roberts MR, Qin L, Zhang D, Smith DH, Tran AC, Dull TJ, et al. Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. *Blood.* 1994;84(9):2878-89.
14. Tran AC, Zhang D, Byrn R, and Roberts MR. Chimeric zeta-receptors direct human natural killer (NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes. *Journal of immunology (Baltimore, Md : 1950).* 1995;155(2):1000-9.
15. Masiero S, Del Vecchio C, Gavioli R, Mattiuzzo G, Cusi MG, Micheli L, et al. T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120. *Gene therapy.* 2005;12(4):299-310.
16. Mitsuyasu RT, Anton PA, Deeks SG, Scadden DT, Connick E, Downs MT, et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected

subjects. *Blood.* 2000;96(3):785-93.
17. Deeks SG, Wagner B, Anton PA, Mitsuyasu RT, Scadden DT, Huang C, et al. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. *Molecular therapy : the journal of the American Society of Gene Therapy.* 2002;5(6):788-97.
18. Walker RE, Bechtel CM, Natarajan V, Baseler M, Hege KM, Metcalf JA, et al. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. *Blood.* 2000;96(2):467-74.
19. Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. *Science translational medicine.* 2012;4(132):132ra53.
20. Colovos C, Villena-Vargas J, and Adusumilli PS. Safety and stability of retrovirally transduced chimeric antigen receptor T cells. *Immunotherapy.* 2012;4(9):899-902.
21. Liu L, Patel B, Ghanem MH, Bundoc V, Zheng Z, Morgan RA, et al. Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity. *Journal of virology.* 2015;89(13):6685-94.
22. Liu B, Zou F, Lu L, Chen C, He D, Zhang X, et al. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy. *Journal of virology.* 2016;90(21):9712-24.
23. Ali A, Kitchen SG, Chen ISY, Ng HL, Zack JA, and Yang OO. HIV-1-Specific Chimeric Antigen Receptors Based on Broadly Neutralizing Antibodies. *Journal of virology.* 2016;90(15):6999-7006.
24. Hale M, Mesojednik T, Romano Ibarra GS, Sahni J, Bernard A, Sommer K, et al. Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells. *Molecular therapy : the journal of the American Society of Gene Therapy.* 2017;25(3):570-9.
25. Ghanem MH, Bolivar-Wagers S, Dey B, Hajduczki A, Vargas-Inchaustegui DA, Danielson DT, et al. Bispecific chimeric antigen receptors targeting the CD4 binding site and high-mannose Glycans of gp120 optimized for anti-human immunodeficiency virus potency and breadth with minimal immunogenicity. *Cytotherapy.* 2018;20(3):407-19.
26. Anthony-Gonda K, Bardhi A, Ray A, Flerin N, Li M, Chen W, et al. Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model. *Science translational medicine.* 2019;11(504).
27. Zou F, Lu L, Liu J, Xia B, Zhang W, Hu Q, et al. Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56. *Nature communications.* 2019;10(1):4109.
28. Li JZ, Etemad B, Ahmed H, Aga E, Bosch RJ, Mellors JW, et al. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. *AIDS (London, England).* 2016;30(3):343-53.
29. Kilby JM, Bucy RP, Mildvan D, Fischl M, Santana-Bagur J, Lennox J, et al. A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024). *J Infect*

Dis. 2006;194(12):1672-6.
30. Jacobson JM, Pat Bucy R, Spritzler J, Saag MS, Eron JJ, Jr., Coombs RW, et al. Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. *J Infect Dis.* 2006;194(5):623-32.
31. Skiest DJ, Su Z, Havlir DV, Robertson KR, Coombs RW, Cain P, et al. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. *J Infect Dis.* 2007;195(10):1426-36.
32. Schooley RT, Spritzler J, Wang H, Lederman MM, Havlir D, Kuritzkes DR, et al. AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. *J Infect Dis.* 2010;202(5):705-16.
33. Goulder PJ, and Walker BD. HIV and HLA class I: an evolving relationship. *Immunity.* 2012;37(3):426-40.
34. Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. *Blood.* 2012;119(17):3940-50.
35. Fraietta JA, Nobles CL, Sammons MA, Lundh S, Carty SA, Reich TJ, et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. *Nature.* 2018;558(7709):307-12.
36. Fischer M, Wong JK, Russenberger D, Joos B, Opravil M, Hirschel B, et al. Residual cell-associated unspliced HIV-1 RNA in peripheral blood of patients on potent antiretroviral therapy represents intracellular transcripts. *Antivir Ther.* 2002;7(2):91-103.
37. Fischer M, Joos B, Wong JK, Ott P, Opravil M, Hirschel B, et al. Attenuated and nonproductive viral transcription in the lymphatic tissue of HIV-1-infected patients receiving potent antiretroviral therapy. *J Infect Dis.* 2004;189(2):273-85.
38. Pasternak AO, Jurriaans S, Bakker M, Prins JM, Berkhout B, and Lukashov VV. Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome. *PloS one.* 2009;4(12):e8490.
39. Pasternak AO, and Berkhout B. What do we measure when we measure cell-associated HIV RNA. *Retrovirology.* 2018;15(1):13.
40. Bruner KM, Wang Z, Simonetti FR, Bender AM, Kwon KJ, Sengupta S, et al. A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. *Nature.* 2019;566(7742):120-5.
41. Rothenberger MK, Keele BF, Wietgrefe SW, Fletcher CV, Beilman GJ, Chipman JG, et al. Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption. *Proceedings of the National Academy of Sciences of the United States of America.* 2015;112(10):E1126-34.
42. Kearney MF, Wiegand A, Shao W, Coffin JM, Mellors JW, Lederman M, et al. Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy. *Journal of virology.* 2016;90(3):1369-76.
43. Bednar MM, Hauser BM, Zhou S, Jacobson JM, Eron JJ, Jr., Frank I, et al. Diversity and Tropism of HIV-1 Rebound Virus Populations in Plasma Level After Treatment

Discontinuation. *J Infect Dis.* 2016;214(3):403-7.
44. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. *Science (New York, NY).* 2010;329(5993):811-7.
45. Wu X, Wang C, O'Dell S, Li Y, Keele BF, Yang Z, et al. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site. *Journal of virology.* 2012;86(10):5844-56.
46. Lynch RM, Wong P, Tran L, O'Dell S, Nason MC, Li Y, et al. HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies. *Journal of virology.* 2015;89(8):4201-13.
47. Utachee P, Nakamura S, Isarangkura-Na-Ayuthaya P, Tokunaga K, Sawanpanyalert P, Ikuta K, et al. Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain. *Journal of virology.* 2010;84(9):4311-20.
48. Shang H, Han X, Shi X, Zuo T, Goldin M, Chen D, et al. Genetic and neutralization sensitivity of diverse HIV-1 env clones from chronically infected patients in China. *The Journal of biological chemistry.* 2011;286(16):14531-41.
49. Guo D, Shi X, Arledge KC, Song D, Jiang L, Fu L, et al. A single residue within the V5 region of HIV-1 envelope facilitates viral escape from the broadly neutralizing monoclonal antibody VRC01. *The Journal of biological chemistry.* 2012;287(51):43170-9.
50. Liao HX, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. *Nature.* 2013;496(7446):469-76.
51. Zhou T, Doria-Rose NA, Cheng C, Stewart-Jones GBE, Chuang GY, Chambers M, et al. Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. *Cell reports.* 2017;19(4):719-32.
52. Parks KR, MacCamy AJ, Trichka J, Gray M, Weidle C, Borst AJ, et al. Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization. *Cell reports.* 2019;29(10):3060-72.e7.
53. Zhou P, Wang H, Fang M, Li Y, Wang H, Shi S, et al. Broadly resistant HIV-1 against CD4-binding site neutralizing antibodies. *PLoS pathogens.* 2019;15(6):e1007819.
54. Hraber P, Korber B, Wagh K, Giorgi EE, Bhattacharya T, Gnanakaran S, et al. Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants. *Viruses.* 2015;7(10):5443-75.
55. Laird GM, Eisele EE, Rabi SA, Lai J, Chioma S, Blankson JN, et al. Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. *PLoS pathogens.* 2013;9(5):e1003398.
56. Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. *Cell.* 2013;155(3):540-51.
57. Chun TW, Justement JS, Lempicki RA, Yang J, Dennis G, Jr., Hallahan CW, et al. Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. *Proceedings of the National Academy of Sciences of the United States of America.* 2003;100(4):1908-13.

58. Gandhi RT, Cyktor JC, Bosch RJ, Mar H, Laird GM, Martin A, et al. Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy. *J Infect Dis.* 2021;223(2):225-33.
59. Zhang LX, Jiao YM, Zhang C, Song JW, Fan X, Xu RN, et al. HIV Reservoir Decay and CD4 Recovery Associated With High CD8 Counts in Immune Restored Patients on Long-Term ART. *Frontiers in immunology.* 2020;11:1541.
60. Bedoui S, Heath WR, and Mueller SN. CD4(+) T-cell help amplifies innate signals for primary CD8(+) T-cell immunity. *Immunological reviews.* 2016;272(1):52-64.
61. Zander R, Schauder D, Xin G, Nguyen C, Wu X, Zajac A, et al. CD4(+) T Cell Help Is Required for the Formation of a Cytolytic CD8(+) T Cell Subset that Protects against Chronic Infection and Cancer. *Immunity.* 2019;51(6):1028-42.e4.
62. Abdel-Mohsen M, Richman D, Siliciano RF, Nussenzweig MC, Howell BJ, Martinez-Picado J, et al. Recommendations for measuring HIV reservoir size in cure-directed clinical trials. *Nature medicine.* 2020;26(9):1339-50.
63. Xu L, Wang J, Liu Y, Xie L, Su B, Mou D, et al. CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia. *The New England journal of medicine.* 2019;381(13):1240-7.
64. Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. *The New England journal of medicine.* 2014;370(10):901-10.
65. Tebas P, Jadlowsky JK, Shaw PA, Tian L, Esparza E, Brennan AL, et al. CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. *The Journal of clinical investigation.* 2021;131(7).
66. Rust BJ, Kean LS, Colonna L, Brandenstein KE, Poole NH, Obenza W, et al. Robust expansion of HIV CAR T cells following antigen boosting in ART-suppressed nonhuman primates. *Blood.* 2020;136(15):1722-34.
67. Liu C, Ma X, Liu B, Chen C, and Zhang H. HIV-1 functional cure: will the dream come true? *BMC medicine.* 2015;13:284.
68. Muul LM, Tuschong LM, Soenen SL, Jagadeesh GJ, Ramsey WJ, Long Z, et al. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. *Blood.* 2003;101(7):2563-9.
69. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. *Blood.* 2010;115(5):925-35.
70. Wang X, and Riviere I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. *Molecular therapy oncolytics.* 2016;3:16015.
71. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. *Science (New York, NY).* 1997;276(5319):1719-24.
72. Zhang Y, Fan M, Geng G, Liu B, Huang Z, Luo H, et al. A novel HIV-1-encoded microRNA enhances its viral replication by targeting the TATA box region. *Retrovirology.* 2014;11:23.
73. Pan T, Song Z, Wu L, Liu G, Ma X, Peng Z, et al. USP49 potently stabilizes APOBEC3G protein by removing ubiquitin and inhibits HIV-1 replication. *eLife.* 2019;8.

74. Pentikainen PJ, Saraheimo M, Schwartz JI, Amin RD, Schwartz MS, Brunner-Ferber F, et al. Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. *Journal of clinical pharmacology.* 1992;32(2):136-40.
75. Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, Keele BF, et al. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. *Journal of virology.* 2008;82(8):3952-70.
76. Jordan MR, Kearney M, Palmer S, Shao W, Maldarelli F, Coakley EP, et al. Comparison of standard PCR/cloning to single genome sequencing for analysis of HIV-1 populations. *J Virol Methods.* 2010;168(1-2):114-20.

Author contributions

BF.L., LH.L. and H.Z. designed the experiments, performed most of these experiments, analyzed the data, and manuscript writing; WY.Z., BJ.X., SL.J., YY.D., F.Z., R.L., LJ.L., SZ.C., YH.L., QF.H., YT.L., YW.Z., ZP.H. and X.Z made substantial contributions to the acquisition of data and data analyses; XJ.C., XP.T., T.P. and WP.C. provided scientific expertise and supervised analysis of clinical data; T.P, LH.L. and H.Z. have full access to all data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors reviewed and approved the final version of the report.

Acknowledgements

This work was supported by the National Special Research Program of China for Important Infectious Diseases (2017ZX10202102 and 2018ZX10302103) to H.Z, LH.L and T.P; the Important Key Program of Natural Science Foundation of China (81730060) to H.Z; the Joint-innovation Program in Healthcare for Special Scientific Research Projects of Guangzhou (201803040002) to H.Z. LH. L, and WP. C; the Natural Science Foundation of Guangdong Province (2020A1515011108) to BF.L.

Data and materials availability

All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials.

Table 1. Baseline clinical characteristics of enrolled participants.

ID	Age	Gender	Race	Years since HIV-1 dx	Years since first ART	ART at Screening*	Reported CD4 nadir	CD4 Count (Scr)	HIV-1 RNA (cp/ml) (Scr)	Weeks to viral rebound
001	40	M	Asian	7.4	7.5	TDF+3TC+RAL	272	551	<20	-
002	31	M	Asian	4.0	3.9	TDF+3TC+EFV	267	842	<20	10
003	29	M	Asian	2.1	2.1	TDF+3TC+DTG	342	407	<20	4
004	29	M	Asian	4.8	4.6	AZT+3TC+EFV	160	416	<20	5
005	35	M	Asian	6.6	4.0	TDF+3TC+EFV	343	441	<20	5
006	31	M	Asian	6.7	4.4	TDF+3TC+LPV/r	52	620	<20	3
007	30	M	Asian	4.8	4.6	TDF+3TC+EFV	277	597	<20	-
008	47	M	Asian	5.5	5.6	TDF+3TC+EFV	253	709	<20	-
009	39	M	Asian	9.4	5.7	TDF+3TC+EFV	211	440	<20	-
010	37	M	Asian	7.1	4.7	3TC+LPV/r	83	693	<20	-
011	36	M	Asian	4.0	3.9	TDF+3TC+EFV	63	380	<20	
012	30	M	Asian	7.4	2.8	TDF+3TC+EFV	285	729	<20	-
013	26	M	Asian	3.1	3.1	TDF+3TC+EFV	378	467	<20	-
014	29	M	Asian	3.5	3.5	TDF+3TC+EFV	353	752	<20	-
015	26	M	Asian	2.1	1.8	TDF+3TC+EFV	465	684	<20	5

* TDF, tenofovir disoproxil fumarate; AZT, Zidovudine; 3TC, lamivudine; EFV, efavirenz; LPV/r, lopinavir/ritonavir; DTG, dolutegravir; RAL, raltegravir.

Table 2. Baseline demographics of participants.

Characteristics of the Participants at Baseline		
Sex — no. (%)	Male	15 (100)
	Female	0 (0)
Age (year) — Median (range)		31 (26-47)
Race or ethnic group — no. (%)	Asian	15 (100)
	Other races	0 (0)
HIV-1 RNA (Screen)— copies/no. (%)	<20 copies/ml	15 (100)
	≥20 copies/ml	0 (0)
Nadir CD4$^+$ T-cell count — no. (%)	<200 cells/μl	4 (26.7)
	200–500 cells/μl	11 (73.3)
	>500 cells/μl	0 (0)
	Unknown	0 (0)
CD4$^+$ T-cell Count (Screen) — no. (%)	<200 cells/μl	0 (0)
	200–500 cells/μl	6 (40)
	>500 cells/μl	9 (60)
	Unknown	0 (0)
Years after diagnosis — Median (range)		4.8 (2.1-9.4)
Years on ART — Median (range)		4.0 (1.8-7.5)
ART regimen — no. (%) **	2 NRTI + 1 NNRTI	11 (73.3)
	2 NRTI + 1 PI	1 (6.67)
	NRTI + 1 PI	1 (6.67)
	2 NRTI + 1 INSTI	2 (13.3)

** NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; INSTI, integrase strand transfer inhibitor.



Figure 1. Schematic of the clinical study. The clinical trial was divided into four parts: blood drawing and CAR-T cell preparation, CAR-T cell infusion, ATI, and ART re-initiation after viral rebound. The safety laboratory values and HIV-1 viral load were monitored at regular intervals throughout the study.

A



B



C



Figure 2. **Plasma viremia in HIV-1-infected patients after discontinuation of ART. (A)** Panel A shows the schematic representation of the lentiviral vectors carrying a gp120-specific CAR moiety containing CD28 and 4-1BB (CD137) co-stimulatory domains, followed by a herpes simplex virus-1 thymidine kinase (TK) and a truncated CD19 gene as the suicide genes. A combination of shRNAs, including sh-PD-1, sh-Lag-3, and sh-Tim-3, for preventing exhaustion and increasing the *in vivo* persistence of CAR-T cells, was inserted into the vector. **(B)** Panel B shows the plasma viremia of participants in the study after the ATI of ART (n=6). The limit of detection of HIV-1 RNA level in this assay is 20 copies/ml. **(C)** Panel C shows the Kaplan-Meier curve of plasma viral suppression (<200 copies/ml) after ATI in the trial participants.



Figure 3. Cell-associated viral RNA and *in vivo* CAR-T cell persistence before and after adoptive transfer. (A) Measured CAR$^+$ cell concentrations (per million CD8$^+$ T cells) for the 14 enrolled patients are shown in blue (log10 scale on left), and CA-RNA levels after adoptive transfer (per million CD4$^+$ T cells) are shown in red (log10 scale shown on right). ATI period is shown by shades of grey. **(B)** HIV-1 RNA levels in plasma (copies/ml) are shown in black (log10 scale shown on right) and CA-RNA levels after ATI (per million CD4$^+$ T cells) are shown in red (log10 scale shown on left). ATI periods are shown by shades of grey.

A



B



C



Figure 4. CAR-T treatment decreased the CA-RNA and intact HIV-1 proviruses. (A) Panels show the comparison of CA-RNA before and after administration of CAR-T cells at indicated time-points. Each point represents the mean of triplicate values, left panel: 14 HIV-1-infected participants, right panel: 6 ATI participants; P-values were calculated using the Wilcoxon matched pairs signed-rank test. **(B)** Representative IPDA results from Patients 002 and 015. Boxed areas are expanded to show individual positive droplets. **(C)** Panels show IPDA results in CD4$^+$ T cells from 14 HIV-1-infected participants (left panel) and 6 ATI participants (right panel), before and after CAR-T cell administration. P-values were calculated using the Wilcoxon matched pairs signed-rank test.



Figure 5. Genetic comparison of the circulating latent reservoir and rebound viruses. Panels show maximum likelihood phylogenetic trees of single-genome sequencing-derived Env sequences from cell samples before CAR-T administration and cell/plasma samples from the first and second weeks of detectable viremia. Sequences from pre-CAR-T treatment are shown in blue, and the sequences from week-1 or week-2 of rebound viremia are shown in red, respectively. Genetic distance scale bars are shown for each tree; the bootstrap consensus trees were constructed based on HIV-1 sequences obtained from the corresponding patients. Sequences from pre-CAR-T treatment were not available in Patient 005.



Figure 6. Rebound virus clonality and resistance to bNAb-derived CAR-T cell-mediated cytotoxicity. (A) Panel A shows the clonal Env mutations on inner domain, V2 loop, loop D, CD4-binding site, and V5 loop after viral rebound in Patients 002 and 006. All sequences were compared to the consensus of the rebound viruses. The residue numbers are based on HIV-1 HXB2 sequence. The top line shows amino acid differences in the pre-CAR-T sequences from the rebound consensus. **(B)** PBMCs were isolated from healthy donors and divided into two populations, the $CD8^+$ T lymphocytes were used to generate CAR-T cells, while the autologous $CD4^+$ T cells were infected with outgrown HIV-1 from pre-CAR-T latent reservoir (LR) or rebound reservoir (RD) (1 ng/ml p24). Six days after HIV-1 infection, antiretroviral compounds (azidothymidine and lopinavir) were added to the $CD4^+$ T cell culture to inhibit virus production. Then the anti-HIV-1 drugs were withdrawn and CAR or control $CD8^+$ T cells were mixed at 1: 1 ratio; every 2 days the cultures were tested for the presence of p24 in the supernatant, using ELISA. Grey shade represents the addition of antiviral drugs. **(C)** HIV-1 Env derived from pre-CAR-T latent reservoir or rebound reservoir was ectopically expressed on the HEK293T cell-line, these target cell lines were compared for changes in sensitivity to CAR-T-mediated specific-cytotoxicity. Env dervied from $HIV\text{-}1_{NL4\text{-}3}$ served as the positive control. Direct killing of target cell lines was was tested after 24-hour co-culture by detecting LDH release. A two-sided P-value for the estimated difference in pre-CAR-T and rebound resistance was calculated. Data represent the mean of triplicate values, and error bars represent SEM. P-values were calculated using the two-tailed unpaired Student's t-test with equal variances.